.: ORİJİNAL ARAŞTIRMA
Assessment of Vision-Related Quality of Life in Patients with Neovascular Age-Related Macular Degeneration During COVID-19 Pandemic: Retrospective Study
Neovasküler Yaşa Bağlı Makula Dejeneransı Olan Hastalarda COVID-19 Pandemisi Sırasında Görme İlişkili Yaşam Kalitesinin Değerlendirilmesi: Retrospektif Çalışma
Turkiye Klinikleri J Ophthalmol. 2022;31(4):248-53
doi: 10.5336/ophthal.2022-89993
Makale Dili: EN
Tam Metin
ABSTRACT
Objective: To evaluate vision-related quality of life (QoL) using National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) in neovascular age-related macular degeneration (nAMD) patients during coronavirus disease-2019 (COVID-19) pandemic. Material and Methods: nAMD patients whose intravitreal injection had to be postponed due to restrictions of COVID-19 lockdown between April and June 2020, NEI-VFQ-25 was administered last visit pre-COVID-19 and first visit during COVID-19. NEI-VFQ-25 scores, best-corrected visual acuity (BCVA) and central macular thickness (CMT) were compared between visits. Results: Fifty six patients with nAMD were participitated in the study. The composite score of NEIVFQ-25 was statistically significantly lower at first visit during COVID-19 when compared with at last pre-COVID-19 (95% confidence interval, 2.33-4.24; p=0.000). Decrease in NEI-VFQ-25 composite score was moderately associated with an impairment in BCVA at first visit during COVID-19 and duration of treatment delay after adjusting for age, gender, BCVA at last visit pre COVID-19 and CMT (β coefficient=0.42 and 0.41 and p=0.016 and 0.015). Conclusion: Negative impacts of delayed treatment during COVID-19 pandemic were observed by decrease NEI-VFQ-25 composite scores in patients with nAMD observed on psychological well-being and ability of performing daily life activities that depend on visual function.
Keywords: Coronavirus pandemic; neovascular age-related macular degeneration; vision-related quality of life
Objective: To evaluate vision-related quality of life (QoL) using National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) in neovascular age-related macular degeneration (nAMD) patients during coronavirus disease-2019 (COVID-19) pandemic. Material and Methods: nAMD patients whose intravitreal injection had to be postponed due to restrictions of COVID-19 lockdown between April and June 2020, NEI-VFQ-25 was administered last visit pre-COVID-19 and first visit during COVID-19. NEI-VFQ-25 scores, best-corrected visual acuity (BCVA) and central macular thickness (CMT) were compared between visits. Results: Fifty six patients with nAMD were participitated in the study. The composite score of NEIVFQ-25 was statistically significantly lower at first visit during COVID-19 when compared with at last pre-COVID-19 (95% confidence interval, 2.33-4.24; p=0.000). Decrease in NEI-VFQ-25 composite score was moderately associated with an impairment in BCVA at first visit during COVID-19 and duration of treatment delay after adjusting for age, gender, BCVA at last visit pre COVID-19 and CMT (β coefficient=0.42 and 0.41 and p=0.016 and 0.015). Conclusion: Negative impacts of delayed treatment during COVID-19 pandemic were observed by decrease NEI-VFQ-25 composite scores in patients with nAMD observed on psychological well-being and ability of performing daily life activities that depend on visual function.
Keywords: Coronavirus pandemic; neovascular age-related macular degeneration; vision-related quality of life
ÖZET
Amaç: Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] pandemisi sırasında, neovasküler tip yaşa bağlı makula dejeneransı (nYBMD) olan hastalarda Ulusal Göz Hastalıkları Enstitüsü Görme İşlevi Ölçeği-25 [National Eye InstituteVisual Function Questionnaire-25 (NEI-VFQ-25)] kullanarak görme ilişkili yaşam kalitesini değerlendirmektir. Gereç ve Yöntemler: Nisan ve Haziran 2020 arasında COVID-19 kısıtlamaları nedeniyle intravitreal enjeksiyonu ertelenen nYBMD hastalarına NEI-VFQ-25 ölçeği COVID-19 öncesi son muayenede ve COVID-19 sırasındaki ilk muayenede uygulandı. Muayeneler arasındaki NEI-VFQ-25 skorları, en iyi düzeltilmiş görme keskinliği (EİDGK) ve santral makula kalınlığı (SMK) karşılaştırıldı. Bulgular: Çalışmaya 56 nYBMD'li hasta katıldı. NEI-VFQ-25 bileşik skoru COVID-19 öncesi son muayene ile karşılaştırıldığında COVID-19 sırasındaki ilk muayenede istatistiksel olarak anlamlı daha düşüktü (%95 güven aralığı, 2,33-4,24; p=0,000). Yaş, cinsiyet, COVID-19 öncesi son muayene EİDGK ve SMK için düzeltme yapıldıktan sonra NEI-VFQ-25 bileşik skorundaki azalma COVID-19 sırasındaki ilk muayenede EİDGK'deki azalma ve tedavi gecikme süresi ile orta derecede ilişkiliydi (β katsayısı=0,42 ve 0,41; p=0,016 ve p=0,015). Sonuç: nYBMD'li hastalarda bileşik NEI-VFQ25 bileşik skorundaki azalmayla birlikte psikolojik iyi olma ve görme fonksiyonuna bağlı günlük yaşam aktivitelerini gerçekleştirme yeteneği üzerinde COVID-19 pandemisi sürecindeki gecikmiş tedavinin olumsuz etkileri gözlemlenmiştir.
Anahtar Kelimeler: Koronavirüs pandemisi; neovasküler yaşa bağlı makula dejeneransı; görme ilişkili yaşam kalitesi
Amaç: Koronavirüs hastalığı-2019 [coronavirus disease-2019 (COVID-19)] pandemisi sırasında, neovasküler tip yaşa bağlı makula dejeneransı (nYBMD) olan hastalarda Ulusal Göz Hastalıkları Enstitüsü Görme İşlevi Ölçeği-25 [National Eye InstituteVisual Function Questionnaire-25 (NEI-VFQ-25)] kullanarak görme ilişkili yaşam kalitesini değerlendirmektir. Gereç ve Yöntemler: Nisan ve Haziran 2020 arasında COVID-19 kısıtlamaları nedeniyle intravitreal enjeksiyonu ertelenen nYBMD hastalarına NEI-VFQ-25 ölçeği COVID-19 öncesi son muayenede ve COVID-19 sırasındaki ilk muayenede uygulandı. Muayeneler arasındaki NEI-VFQ-25 skorları, en iyi düzeltilmiş görme keskinliği (EİDGK) ve santral makula kalınlığı (SMK) karşılaştırıldı. Bulgular: Çalışmaya 56 nYBMD'li hasta katıldı. NEI-VFQ-25 bileşik skoru COVID-19 öncesi son muayene ile karşılaştırıldığında COVID-19 sırasındaki ilk muayenede istatistiksel olarak anlamlı daha düşüktü (%95 güven aralığı, 2,33-4,24; p=0,000). Yaş, cinsiyet, COVID-19 öncesi son muayene EİDGK ve SMK için düzeltme yapıldıktan sonra NEI-VFQ-25 bileşik skorundaki azalma COVID-19 sırasındaki ilk muayenede EİDGK'deki azalma ve tedavi gecikme süresi ile orta derecede ilişkiliydi (β katsayısı=0,42 ve 0,41; p=0,016 ve p=0,015). Sonuç: nYBMD'li hastalarda bileşik NEI-VFQ25 bileşik skorundaki azalmayla birlikte psikolojik iyi olma ve görme fonksiyonuna bağlı günlük yaşam aktivitelerini gerçekleştirme yeteneği üzerinde COVID-19 pandemisi sürecindeki gecikmiş tedavinin olumsuz etkileri gözlemlenmiştir.
Anahtar Kelimeler: Koronavirüs pandemisi; neovasküler yaşa bağlı makula dejeneransı; görme ilişkili yaşam kalitesi
REFERANSLAR:
- Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. [PubMed] [PMC]
- Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020;91(1):157-60.
- Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al; Vision Loss Expert Group of the Global Burden of Disease Study. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol. 2014;98(5):629-38. [Crossref] [PubMed]
- Congdon N, O'Colmain B, Klaver CC, Klein R, Mu-oz B, Friedman DS, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122(4):477-85. [Crossref] [PubMed]
- Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, et al. Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology. 2001;108(10):1893-900; discussion 1900-1. [Crossref] [PubMed]
- Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol. 1998;116(4):514-20. [Crossref] [PubMed]
- Dong LM, Childs AL, Mangione CM, Bass EB, Bressler NM, Hawkins BS, et al; Submacular Surgery Trials Research Group. Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol. 2004;138(1):91-108. [Crossref] [PubMed]
- Finger RP, Guymer RH, Gillies MC, Keeffe JE. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology. 2014;121(6):1246-51. [Crossref] [PubMed]
- Submacular Surgery Trials Research Group. Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. Ophthalmic Epidemiol. 2007;14(4):205-15. [Crossref] [PubMed]
- Leys A, Zlateva G, Shah SN, Patel M. Quality of life in patients with age-related macular degeneration: results from the VISION study. Eye (Lond). 2008;22(6):792-8. [Crossref] [PubMed]
- Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(2):246-52. [Crossref] [PubMed]
- Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. Optic neuritis treatment trial. Invest Ophthalmol Vis Sci. 2000;41(5):1017-21. [PubMed]
- Toprak AB, Eser E, Güler C. Görme ile ilgili sağlıkta yaşam kalitesi ölçekleri ve Ulusal Göz Hastalıkları Enstitüsü Görme işlevi ölçeğinin (NEI-VFQ) Türkçe çevirisi [Vision-related health quality of life scales and the Turkish translation of the National Eye Institute Visual Function Questionnaire]. T.Oft.Gaz. 2005;35:453-4. [Link]
- Yuzawa M, Fujita K, Tanaka E, Wang EC. Assessing quality of life in the treatment of patients with age-related macular degeneration: clinical research findings and recommendations for clinical practice. Clin Ophthalmol. 2013;7:1325-32. [Crossref] [PubMed] [PMC]
- Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators. Arch Ophthalmol. 1998;116(11):1496-504. [Crossref] [PubMed]
- Lindblad AS, Clemons TE. Responsiveness of the National Eye Institute Visual Function Questionnaire to progression to advanced age-related macular degeneration, vision loss, and lens opacity: AREDS Report no. 14. Arch Ophthalmol. 2005;123(9):1207-14. [Crossref] [PubMed] [PMC]
- Chang AA, Broadhead GK, Hong T, Joachim N, Syed A, Schlub TE, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomes. Ophthalmic Res. 2015;55(2):84-90. [Crossref] [PubMed]
- Chia EM, Mitchell P, Rochtchina E, Foran S, Wang JJ. Unilateral visual impairment and health related quality of life: the Blue Mountains Eye Study. Br J Ophthalmol. 2003;87(4):392-5. [Crossref] [PubMed] [PMC]
- Berdeaux GH, Nordmann JP, Colin E, Arnould B. Vision-related quality of life in patients suffering from age-related macular degeneration. Am J Ophthalmol. 2005;139(2):271-9. [Crossref] [PubMed]
.: İşlem Listesi